1689P Adverse event management during treatment with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1: Treatment guidelines based on experience in clinical trials
Year: 2021
Type: article
Source: Annals of Oncology
Authors: J. Gulley, M.E. Lacouture, A. Spira, H. Verdaguer Mata, C. Yoo, B.C. Cho, C. Helwig, T. Halady, C. Valencia, M. Bajars, J. Strauss, I. Brownell
Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research, Memorial Sloan Kettering Cancer Center, Virginia Cancer Specialists, Vall d'Hebron Hospital Universitari, Asan Medical Center, Yonsei University, Yonsei Cancer Hospital, Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany), National Institute of Arthritis and Musculoskeletal and Skin Diseases
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3203415203